APA
Dogra S., D S K., Budamakuntla L., Srinivas C. R., Khopkar U., Gupta S., Shetty N., Pratap D. V. S., Gopal M. G., Rao T. N., Garg V., Sumathy T. K., Saraswat A., Bhat R., Kura M., Pandey N., Shah R., Sai Krishna K., Padmaja D., Manmohan G., M S R., Barve A. & Montero E. (20151006). Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled study. : Journal of the American Academy of Dermatology.
Chicago
Dogra Sunil, D S Krupashankar, Budamakuntla Leelavathy, Srinivas C R, Khopkar Uday, Gupta Sandesh, Shetty Narendra, Pratap Dasiga Venkata Subrahmanya, Gopal M G, Rao T Narayana, Garg Vijay, Sumathy T K, Saraswat Abir, Bhat Ramesh, Kura Mahendra, Pandey Neeraj, Shah Radha, Sai Krishna Kotla, Padmaja Dalavai, Manmohan G, M S Ramakrishnan, Barve Abhijit and Montero Enrique. 20151006. Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled study. : Journal of the American Academy of Dermatology.
Harvard
Dogra S., D S K., Budamakuntla L., Srinivas C. R., Khopkar U., Gupta S., Shetty N., Pratap D. V. S., Gopal M. G., Rao T. N., Garg V., Sumathy T. K., Saraswat A., Bhat R., Kura M., Pandey N., Shah R., Sai Krishna K., Padmaja D., Manmohan G., M S R., Barve A. and Montero E. (20151006). Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled study. : Journal of the American Academy of Dermatology.
MLA
Dogra Sunil, D S Krupashankar, Budamakuntla Leelavathy, Srinivas C R, Khopkar Uday, Gupta Sandesh, Shetty Narendra, Pratap Dasiga Venkata Subrahmanya, Gopal M G, Rao T Narayana, Garg Vijay, Sumathy T K, Saraswat Abir, Bhat Ramesh, Kura Mahendra, Pandey Neeraj, Shah Radha, Sai Krishna Kotla, Padmaja Dalavai, Manmohan G, M S Ramakrishnan, Barve Abhijit and Montero Enrique. Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled study. : Journal of the American Academy of Dermatology. 20151006.